Biosimilar therapeutic agents: Issues with bioequivalence and immunogenicity

European Journal of Clinical Investigation

Volumn 34, Issue 12, 2004, Pages 797-799

  Schellekens, Huub ^a,b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; PREDNISONE; RECOMBINANT BETA INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT HIRUDIN; RECOMBINANT INTERLEUKIN 2; STREPTOKINASE;

BIOEQUIVALENCE; BIOTECHNOLOGY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; EDITORIAL; HUMAN; IMMUNOGENICITY; MOLECULAR SIZE; PATENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURE RED CELL ANEMIA;

DRUGS, GENERIC; EUROPE; HUMANS; LEGISLATION, DRUG; RECOMBINANT PROTEINS; THERAPEUTIC EQUIVALENCY;

EID: 10644268697     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01428.x     Document Type: Editorial

References (16)

1. European Parliament and Council. Regulation (EC) no. 726/2004 of the European Parliament. Europa L136 2004;47.
2. European Parliament and Council. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004. Europa L136 2004;47.
3. InPharma.com. Europe looks forward to years of generic growth. Urch Publishing Ltd, London, United Kingdom. Available at: http://www.inpharm.com/ External/InpH/1,1-0-0-0-inp_intelligence_art-0-10472,00.html. Accessed 16 January 2004.
4. Lynch M, Pentecost BL, Littler WA, Stockley RA. The distribution of antibodies to streptokinase. Postgrad Med J 1996;72:290-2.
5. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-91.
6. Antonelli G. Antibodies to interferon in patients undergoing IFN therapy: an update. J Biol Regul Homeost Agents 1995;9:123-31.
7. Allegretta M, Atkins MB, Dempsey RA, Bradley EC, Konrad MW, Childs A et al. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J Clin Immunol 1986;6:481-90.
8. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
9. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19 (Suppl. 2): ii1-47.
10. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-62.
11. Chamberlain P. Immunogenicity of therapeutic proteins. Part 2: Measurement, prediction, minimisation and regulatory consequences of immunogenicity. The Regulatory Review 2002;5(6):4-10.
12. Committee for Proprietary Medicinal Products. Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance. Non-Clinical and Clinical Issues. London: The European Agency for the Evaluation of Medicinal products. Evaluation of Medicines for Human Use; 2003. EMEA/CPMP/3097/02/Final.
13. Committee for Proprietary Medicinal Products. Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance. Quality issues: The European Agency for the Evaluation of Medicinal products. Evaluation of Medicines for Human Use; 2003: EMEA/CPMP/BWP/3207/00/Rev 1.
14. Nihalani P, Agrawal M, Anvekar A. Multi-source biopharmaceuticals: a new perspective. Clin Res Reg Affairs 2002;19:367-80.
15. Ahr G, Voith B, Kuhlmann J. Guidances related to bioavailability and bioequivalence: European industry perspective. Eur J Drug Metab Pharmacokinet 2000;25:25-7.
16. Chamberlain P. Immunogenicity of therapeutic proteins. Part 1: Causes and clinical manifestations of immunogenicity. The Regulatory Review 2002;5(5):4-9.